Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Brii Biosciences Limited (2137) Stock Price & Analysis

3 Followers

2137 Stock Chart & Stats

HK$1.03HK$0.04(4.59%)
At close: 4:00 PM GMT+8
HK$0.85HK$0.9HK$0.95HK$1Aug 10Aug 24Sep 7Sep 21Oct 5Oct 20Nov 2
Day’s Range
HKD 0.97 - HKD 1.03
52-Week Range
HKD 0.82 - HKD 1.90
Previous Close
HKD 0.98
Volume
N/A
Average Volume (3M)
591.54K
Market Cap
HKD 708.66M
Enterprise Value
-HKD 1.40B
Total Cash (Recent Filing)
HKD 1.77B
Total Debt (Recent Filing)
HKD 6.18M
Price to Earnings (P/E)
―
Beta
1.20
Next Earnings
Mar 19, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage And Positive Equity

Very low leverage reduces financial risk and preserves flexibility to fund operations, development programs, and commercialization efforts. Sizable positive equity provides a cushion against ongoing losses, although the company’s capital base has previously been pressured by accumulated losses.

Improved 2025 Loss And Cash Burn

The reduction in annual losses and cash outflow indicates some progress in financial discipline relative to 2024. If maintained, this improvement could extend the company’s liquidity runway and reduce the pace at which external funding or existing cash resources are consumed.

Partner-enabled Commercialization Model

A partner-enabled model can give Brii access to drug candidates, development expertise, and commercialization capabilities without bearing every activity alone. Significant partnerships may also create milestone, royalty, or cost-sharing opportunities that support longer-term asset monetization.

Bears Say

Persistent Unprofitable Operations

Ongoing losses and deeply negative margins show that the business has not yet established sustainable economic profitability. Continued unprofitable operations can constrain reinvestment, weaken financial resilience, and make future growth dependent on successfully improving product economics or securing additional funding.

Persistent Operating Cash Burn

Consistently negative operating and free cash flow means the company is not currently funding its activities from internally generated cash. This reduces financial stability over a multi-quarter horizon and leaves continued operations reliant on existing liquidity or external funding.

Sharp Revenue Contraction

A sharp revenue decline undermines evidence of commercial scale and weakens operating leverage, particularly while margins remain deeply negative. Persistent volatility would make planning and investment harder and could delay the path toward a more durable, self-financing business.

Brii Biosciences Limited News

2137 FAQ

What was Brii Biosciences Limited’s price range in the past 12 months?
Brii Biosciences Limited lowest stock price was HK$0.82 and its highest was HK$1.90 in the past 12 months.
What is Brii Biosciences Limited’s market cap?
Brii Biosciences Limited’s market cap is HK$708.66M.
When is Brii Biosciences Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Brii Biosciences Limited’s earnings last quarter?
Brii Biosciences Limited released its earnings results on Aug 20, 2026. The company reported -HK$0.164 earnings per share for the quarter, missing the consensus estimate of -HK$0.129 by -HK$0.035.
Is Brii Biosciences Limited overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Brii Biosciences Limited pay dividends?
Brii Biosciences Limited does not currently pay dividends.
What is Brii Biosciences Limited’s EPS estimate?
Brii Biosciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Brii Biosciences Limited have?
Brii Biosciences Limited has 735,843,600 shares outstanding.
What happened to Brii Biosciences Limited’s price movement after its last earnings report?
Brii Biosciences Limited reported an EPS of -HK$0.164 in its last earnings report, missing expectations of -HK$0.129. Following the earnings report the stock price went up 3.571%.
Which hedge fund is a major shareholder of Brii Biosciences Limited?
Currently, no hedge funds are holding shares in HK:2137
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology